Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Zacks Research

Precigen (NASDAQ:PGEN) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Several other research firms have also weighed in on PGEN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Citizens Jmp increased their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. HC Wainwright upped their price objective on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Citigroup reiterated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Precigen currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Precigen Stock Up 0.3%

Shares of Precigen stock opened at $6.91 on Wednesday. The stock’s 50-day moving average is $5.17 and its 200 day moving average is $4.48. Precigen has a one year low of $1.70 and a one year high of $7.23. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -6.64 and a beta of 1.02. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 4.12.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The business had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen’s revenue was up 6322.7% on a year-over-year basis. Equities research analysts anticipate that Precigen will post -0.02 EPS for the current year.

Insider Buying and Selling at Precigen

In other Precigen news, COO Rutul R. Shah sold 33,772 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $6.50, for a total transaction of $219,518.00. Following the transaction, the chief operating officer owned 497,751 shares in the company, valued at approximately $3,235,381.50. This represents a 6.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Sabzevari sold 346,836 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the transaction, the chief executive officer directly owned 3,768,872 shares in the company, valued at $22,198,656.08. This trade represents a 8.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 956,500 shares of company stock worth $5,248,371. 41.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming bought a new position in Precigen in the 1st quarter valued at about $27,000. NBC Securities Inc. bought a new stake in Precigen during the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd bought a new stake in Precigen during the 3rd quarter worth approximately $39,000. Royal Bank of Canada raised its stake in shares of Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,426 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Precigen in the third quarter worth approximately $41,000. 33.51% of the stock is owned by institutional investors.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 performance and profitability: Precigen reported that PAPZIMEOS revenue reached $53.1 million in the second quarter, roughly doubling sequentially. The company also achieved profitability, while earnings-call coverage highlighted a 145% increase in revenue. These results support the view that PAPZIMEOS is becoming a meaningful commercial product. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: Regulatory and commercial catalysts: FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis, along with seven years of U.S. market exclusivity, strengthens the product’s revenue outlook. Potential European approval and expansion of Precigen’s AdenoVerse Immunotherapy platform—including PRGN-2009—could provide additional growth opportunities. Precigen Strong Buy and PAPZIMEOS Outlook
• Positive Sentiment: Analyst estimates moved higher: HC Wainwright reiterated its Buy rating and $18 price target, raising its FY2027 EPS forecast to $0.44 from $0.34. Estimates for Q4 2026 and each quarter of 2027 were also increased, while the FY2030 forecast rose to $1.49 from $1.44. These revisions signal greater confidence in the company’s earnings trajectory. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually large options activity attracted attention, but the available report does not identify whether the transactions were bullish or bearish. Precigen Unusually Large Options Trading
• Negative Sentiment: One forecast was trimmed: HC Wainwright reduced its FY2028 EPS estimate slightly to $0.71 from $0.72, a minor offset to the broader upward revisions.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.